Goserelin versus cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy in premenopausal patients with node-positive breast cancer: The Zoladex Early Breast Cancer Research Association Study

Journal of Clinical Oncology

Volumn 20, Issue 24, 2002, Pages 4628-4635

  Jonat, W ^{a,b,c,d,e,f,g,h,i,j,k,l,m,n,o}   Kaufmann, M ^{a,b,c,d,e,f,g,h,i,j,k,l,m,n}   Sauerbrei, W ^{a,b,c,d,e,f,g,h,i,j,k,l,m,n}   Blarney, R ^{a,b,c,d,e,f,g,h,i,j,k,l,m,n}   Cuzick, J ^{a,b,c,d,e,f,g,h,i,j,k,l,m,n}   Namer, M ^{a,b,c,d,e,f,g,h,i,j,k,l,m,n}   Fogelman, I ^{a,b,c,d,e,f,g,h,i,j,k,l,m,n}   de Haes, J C ^{a,b,c,d,e,f,g,h,i,j,k,l,m,n}   de Matteis, A ^{a,b,c,d,e,f,g,h,i,j,k,l,m,n}   Stewart, A ^{a,b,c,d,e,f,g,h,i,j,k,l,m,n}   Eiermann, W ^{a,b,c,d,e,f,g,h,i,j,k,l,m,n}   Szakolczai, I ^{a,b,c,d,e,f,g,h,i,j,k,l,m,n}   Palmer, M ^{a,b,c,d,e,f,g,h,i,j,k,l,m,n}   Schumacher, M ^{a,b,c,d,e,f,g,h,i,j,k,l,m,n}   Geberth, M ^{a,b,c,d,e,f,g,h,i,j,k,l,m,n}   Lisboa, B ^{a,b,c,d,e,f,g,h,i,j,k,l,m,n}  

^a UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^b UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^c UNIVERSITY OF FREIBURG   (Germany)

^d Frauenklinik vom Roten Kreuz   (Germany)

^e UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^f UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^g NOTTINGHAM CITY HOSPITAL   (United Kingdom)

^h GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

ⁱ CHRISTIE HOSPITAL   (United Kingdom)

^j ASTRAZENECA   (United Kingdom)

^k INSTITUT DE RECHERCHES INTERNATIONALES SERVIER   (France)

^l ACADEMIC MEDICAL CENTER   (Netherlands)

^m NATIONAL CANCER INSTITUTE   (Italy)

ⁿ NATIONAL INSTITUTE OF ONCOLOGY   (Hungary)

^o UNIVERSITY OF KIEL   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; FLUOROURACIL; GOSERELIN; METHOTREXATE;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; AMENORRHEA; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER HORMONE THERAPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOTOXICITY; DIARRHEA; DRUG EFFECT; EOSINOPHILIA; FEMALE; FOLLOW UP; HORMONAL REGULATION; HOT FLUSH; HUMAN; INFECTION; LEUKOPENIA; MAJOR CLINICAL STUDY; MULTICENTER STUDY; NAUSEA; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; VAGINAL DRYNESS; VOMITING;

AMENORRHEA; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; FEMALE; FLUOROURACIL; FOLLOW-UP STUDIES; GOSERELIN; HUMANS; LYMPH NODES; LYMPHATIC METASTASIS; METHOTREXATE; MIDDLE AGED; PREMENOPAUSE; RECEPTORS, ESTROGEN;

EID: 0037115422     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2002.05.042     Document Type: Article

References (28)

1. Early Breast Cancer Trialists' Collaborative Group: Ovarian ablation in early breast cancer: Overview of the randomized trials. Lancet 348:1189-1196, 1996
2. Scottish Cancer Trials Breast Group and ICRF Breast Unit: Adjuvant ovarian ablation versus CMF chemotherapy in premenopausal women with pathological stage II breast carcinoma: The Scottish trial. Lancet 341:1293-1298, 1993
3. Ejlertsen B, Dombernowsky P, Mouridsen HT, et al: Comparable effect of ovarian ablation (OA) and CMF chemotherapy in premenopausal hormone receptor positive breast cancer patients (PRP). Proc Am Soc Clin Oncol 18:66a, 1999 (abstr 248)
4. Early Breast Cancer Trialists' Collaborative Group: Systemic treatment of early breast cancer by hormonal, cytotoxic or immune therapy: 133 randomized trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Lancet 339:1-15, 71-85, 1992
5. Early Breast Cancer Trialists' Collaborative Group: Tamoxifen for early breast cancer: An overview of the randomized trials. Lancet 351:1451-1467, 1998
6. Pujol P, Daures JP, Thezenas S, et al: Changing estrogen and progesterone receptor patterns in breast carcinoma during the menstrual cycle and menopause. Cancer 83:698-705, 1998
7. Kaufmann M, Jonat W, Kleeberg U, et al: Goserelin, a depot gonadotrophin-releasing hormone agonist in the treatment of premenopausal patients with metastatic breast cancer. J Clin Oncol 7:1113-1119, 1989
8. Blarney RW, Jonat W, Kaufmann M, et al: Goserelin depot in the treatment of premenopausal advanced breast cancer. Eur J Cancer 28A:810-814, 1992
9. Blarney RW, Jonat W, Kaufmann M, et al: Survival data relating to the use of goserelin depot in the treatment of premenopausal advanced breast cancer., Eur J Cancer 29A:1498, 1993 (letter)
10. Bajetta E, Celio L, Zilembo N, et al: Ovarian function suppression with the gonadotrophin-releasing hormone (GnRH) analogue goserelin in premenopausal advanced breast cancer. Tumori 80:28-32, 1994
11. Boccardo F, Rubagotti A, Perrotta A, et al: Ovarian ablation versus goserelin with or without tamoxifen in pre-/perimenopausal patients with advanced breast cancer: Results of a multicentric Italian study. Ann Oncol 5:337-342, 1994
12. Taylor CW, Green S, Dalton WS, et al: Multicenter randomized clinical trial of goserelin versus surgical ovariectomy in premenopausal patients with receptor-positive metastatic breast cancer: An intergroup study. J Clin Oncol 16:994-999, 1998
13. Bonadonna G, Brusamolino E, Valagussa P, et al: Combination chemotherapy as an adjuvant treatment in operable breast cancer. N Engl J Med 294:405-410, 1976
14. Miller AB, Hoogstraten B, Staquet M, et al: Reporting results of cancer treatment. Cancer 47:207-214, 1981
15. Schoenfeld DA: Sample size formula for the proportional-hazard regression model. Biometrics 39:499-503, 1983
16. Boccardo F, Rubagotti A, Amoroso D, et al: Cyclophosphamide, methotrexate, and fluorouracil versus tamoxifen plus ovarian suppression as adjuvant treatment of estrogen receptor-positive pre-/perimenopausal breast cancer patients: Results of the Italian Breast Cancer Adjuvant Study Group 02 randomized trial. J Clin Oncol 18:2718-2727, 2000
17. Jakesz R, Hausmaninger H, Samonigg H, et al: Complete endocrine blockade with tamoxifen and goserelin is superior to CMF in the adjuvant treatment of premenopausal, lymph node-positive and -negative patients with hormone-responsive breast cancer. Breast 10:S10, 2001 (abstr S26) (suppl 1)
18. Wallwiener D, Possinger K, Bondar G, et al: Leuprorelin acetate vs CMF in the adjuvant treatment of premenopausal women with ER/PR-positive node-positive breast cancer: Interim results of the TABLE-study. Proc Am Soc Clin Oncol 20:34a, 2001 (abstr 132)
19. Roche HH, Kerbrat P, Bonneterre J, et al: Complete hormonal blockade versus chemotherapy in premenopausal early-stage breast cancer patients (Pts) with positive hormone-receptor (HR+) and 1 to 3 node-positive (N+) tumor: Results of the FASG 06 trial. Proc Am Soc Clin Oncol 19:72a, 2000 (abstr 279)
20. Early Breast Cancer Trialists' Collaborative Group: Polychemotherapy for early breast cancer: An overview of the randomized trials. Lancet 352:930-942, 1998
21. Goldhirsch A, Colleoni M, Coates AS, et al: Adding adjuvant CMF chemotherapy to either radiotherapy or tamoxifen: Are all CMFs alike'? Ann Oncol 9:489-493, 1998
22. Castiglione-Gertsch M, O'Neill A, Gelber RD, et al: Is the addition of adjuvant chemotherapy always necessary in node negative (N-) pre/perimenopausal breast cancer patients (pts) who receive goserelin? First results of the IBCSG trial VIII. Proc Am Soc Clin Oncol 21:38a, 2002 (abstr 149)
23. Jakesz R, Hausmaninger H, Samonigg H, et al: Comparison of adjuvant therapy with tamoxifen and goserelin vs CMF in premenopausal stage I and II hormone-responsive breast cancer patients: Four-year results of the Austrian Breast Cancer Study Group (ABCSG) trial 5. Proc Am Soc Clin Oncol 18:67a, 1999 (abstr 250)
24. Pritchard KI: Endocrine therapy for breast cancer. Oncology 14:483-492, 2000
25. Klijn JGM, Blarney RW, Boccardo F, et al: Combined tamoxifen and luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist alone in premenopausal advanced breast cancer: A meta-analysis of four randomized trials. J Clin Oncol 19:343-353, 2001
26. Jonat W, Kaufmann M, Blarney RW, et al: A randomized study to compare the effect of the luteinising hormone releasing hormone (LHRH) analogue goserelin with or without tamoxifen in pre- and perimenopausal patients with advanced breast cancer. Eur J Cancer 31A:137-142, 1995
27. Davidson NE, O'Neill A, Vukov A, et al: Effect of chemohormonal therapy in premenopausal, node-positive, receptor-positive breast cancer: An Eastern Cooperative Oncology Group phase III intergroup trial (E5188, INT-0101). Breast 8:232-233, 1999 (abstr 69)
28. Nystedt M, Berglund G, Bolund C, et al: Randomized trial of adjuvant tamoxifen and/or goserelin in premenopausal breast cancer: Self-rated physiological effects and symptoms. Acta Oncol 39:959-968, 2000